Show simple item record

dc.creatorAbdin, Shifaa M.
dc.creatorElgendy, Sara M.
dc.creatorAlyammahi, Shatha K.
dc.creatorAlhamad, Dima W.
dc.creatorOmar, Hany A.
dc.date.accessioned2020-08-05T20:19:57Z
dc.date.available2020-08-05T20:19:57Z
dc.date.created2020
dc.identifier.issn0024-3205spa
dc.identifier.otherhttps://doi.org/10.1016/j.lfs.2020.118054spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/11664
dc.description.abstractThe outbreak of Coronavirus disease 2019 (COVID-19) is the current world health concern, presenting a public health dilemma with ascending morbidity and mortality rates exceeding any previous viral spread, without a standard effective treatment yet. SARS-CoV-2 infection is distinguished with multiple epidemiological and pathological features, one of them being the elevated levels of cytokine release, which in turn trigger an aberrant uncontrolled response known as “cytokine storm”. This phenomenon contributes to severe acute respiratory distress syndrome (ARDS), leading to pneumonia and respiratory failure, which is considered a major contributor to COVID-19-associated fatality rates. Taking into account that the vast majority of the COVID-19 cases are aggravated by the respiratory and multiorgan failure triggered by the sustained release of cytokines, implementing therapeutics that alleviate or diminish the upregulated inflammatory response would provide a therapeutic advantage to COVID-19 patients. Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients. In this review, we have critically compared the clinical impact of several potential therapeutic agents that could block or interfere with the cytokine storm, such as IL-1 inhibitors, IL-6 inhibitors, mast cell targeting agents, and corticosteroids. This work focused on highlighting and contrasting the current success and limitations towards the involvement of these agents in future treatment protocols.spa
dc.format.extent15 páginasspa
dc.format.mimetypeimage/jepgspa
dc.publisherScience Directeng
dc.publisherLife Sciencesspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subjectCytokine stormspa
dc.subjectIL-6 inhibitorsspa
dc.subjectIL-1 inhibitorsspa
dc.subjectJAK inhibitorsspa
dc.subjectHydroxychloroquinespa
dc.subjectMast cell stabilizersspa
dc.subjectDexamethasonespa
dc.titleTackling the cytokine storm in COVID-19, challenges and hopesspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAcceso restringidospa
dc.identifier.doihttps://doi.org/10.1016/j.lfs.2020.118054spa


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record